抗血管生成剂对肝细胞癌实验动物模型的影响。

Effect of antiangiogenic agents on experimental animal models of hepatocellular carcinoma.

作者信息

Qin L X, Tang Z Y, Li X M, Bu W, Xia J L

机构信息

Liver Cancer Institute, Zhongshan Hospital, Shanghai Medical University, PR China.

出版信息

Ann Acad Med Singap. 1999 Jan;28(1):147-51.

PMID:10374041

Abstract

A new therapeutic strategy for treating metastasis in hepatocellular carcinoma (HCC) has entailed the use of antiangiogenic agents such as suramin, BB-94 (Batimastat), TNP-470, and carboxyamido-triazole (CAI, a synthetic inhibitor of non-excitable calcium channels that reversibly inhibits angiogenesis). These agents have been used to treat metastatic model of HCC in nude mouse (LCI-D20 mouse model). The results of these studies are summarized in this paper with emphasis on the inhibitory effects of the drugs on tumour growth, angiogenesis, invasion and metastasis in LCI-D20 mouse models. The results suggest that all of the agents used can significantly inhibit tumour growth, angiogenesis, invasion and metastasis of human HCC in nude mouse models, and may be candidates for the control of recurrence and metastasis after HCC resection.

摘要

一种治疗肝细胞癌（HCC）转移的新治疗策略涉及使用抗血管生成剂，如苏拉明、BB - 94（batimastat）、TNP - 470和羧酰胺三唑（CAI，一种非兴奋性钙通道的合成抑制剂，可可逆地抑制血管生成）。这些药物已被用于治疗裸鼠HCC转移模型（LCI - D20小鼠模型）。本文总结了这些研究结果，重点关注这些药物对LCI - D20小鼠模型中肿瘤生长、血管生成、侵袭和转移的抑制作用。结果表明，所有使用的药物均可显著抑制裸鼠模型中人类HCC的肿瘤生长、血管生成、侵袭和转移，可能是HCC切除术后控制复发和转移的候选药物。